Mitsubishi UFJ Kokusai Asset Management Co. Ltd. boosted its position in shares of Shire PLC (NASDAQ:SHPG) by 16.3% during the second quarter, Holdings Channel reports. The fund owned 12,622 shares of the biopharmaceutical company’s stock after buying an additional 1,772 shares during the period. Mitsubishi UFJ Kokusai Asset Management Co. Ltd.’s holdings in Shire PLC were worth $2,086,000 as of its most recent SEC filing.

A number of other large investors have also recently added to or reduced their stakes in the stock. Whittier Trust Co. increased its stake in Shire PLC by 19.1% in the first quarter. Whittier Trust Co. now owns 573 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 92 shares during the last quarter. Hartford Financial Management Inc. increased its stake in Shire PLC by 5.4% in the second quarter. Hartford Financial Management Inc. now owns 621 shares of the biopharmaceutical company’s stock worth $102,000 after buying an additional 32 shares during the last quarter. Thompson Davis & CO. Inc. increased its stake in Shire PLC by 3.1% in the first quarter. Thompson Davis & CO. Inc. now owns 640 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 19 shares during the last quarter. FTB Advisors Inc. increased its stake in Shire PLC by 11.1% in the first quarter. FTB Advisors Inc. now owns 749 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 75 shares during the last quarter. Finally, North Star Investment Management Corp. increased its stake in Shire PLC by 8.5% in the first quarter. North Star Investment Management Corp. now owns 756 shares of the biopharmaceutical company’s stock worth $132,000 after buying an additional 59 shares during the last quarter. Institutional investors and hedge funds own 20.22% of the company’s stock.

Shares of Shire PLC (NASDAQ SHPG) opened at 147.71 on Wednesday. Shire PLC has a 1-year low of $147.28 and a 1-year high of $209.22.

Shire PLC (NASDAQ:SHPG) last posted its quarterly earnings data on Thursday, August 3rd. The biopharmaceutical company reported $3.73 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.53 by $0.20. Shire PLC had a net margin of 4.70% and a return on equity of 14.10%. The company had revenue of $3.75 billion for the quarter. During the same period last year, the company earned $3.38 earnings per share. The business’s revenue for the quarter was up 54.2% compared to the same quarter last year. On average, equities analysts expect that Shire PLC will post $14.92 EPS for the current fiscal year.

The company also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be given a $0.1527 dividend. This represents a yield of 0.21%. The ex-dividend date is Thursday, September 7th. Shire PLC’s dividend payout ratio (DPR) is currently 40.63%.

TRADEMARK VIOLATION WARNING: “Mitsubishi UFJ Kokusai Asset Management Co. Ltd. Boosts Position in Shire PLC (SHPG)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this news story on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The correct version of this news story can be read at https://www.thecerbatgem.com/2017/08/16/mitsubishi-ufj-kokusai-asset-management-co-ltd-boosts-position-in-shire-plc-shpg.html.

A number of research firms have weighed in on SHPG. Cantor Fitzgerald set a $222.00 price target on Shire PLC and gave the company a “buy” rating in a research report on Saturday, July 1st. Jefferies Group LLC restated a “hold” rating and set a $206.00 price target (down previously from $216.00) on shares of Shire PLC in a research report on Wednesday, August 9th. Barclays PLC downgraded Shire PLC from an “overweight” rating to an “equal weight” rating in a research report on Friday, August 11th. BidaskClub downgraded Shire PLC from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 5th. Finally, Sanford C. Bernstein restated a “market perform” rating and set a $210.00 price target on shares of Shire PLC in a research report on Thursday, July 13th. One analyst has rated the stock with a sell rating, nine have given a hold rating and fourteen have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and a consensus price target of $222.27.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Want to see what other hedge funds are holding SHPG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Shire PLC (NASDAQ:SHPG).

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Stock Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related stocks with our FREE daily email newsletter.